Glenmede Trust Co. NA Sells 27,375 Shares of Gilead Sciences, Inc. $GILD

Glenmede Trust Co. NA cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 221,975 shares of the biopharmaceutical company’s stock after selling 27,375 shares during the period. Glenmede Trust Co. NA’s holdings in Gilead Sciences were worth $30,937,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. State Street Corp raised its holdings in shares of Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after buying an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Finally, Norges Bank purchased a new position in Gilead Sciences during the 4th quarter valued at $2,617,152,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 0.8%

Shares of NASDAQ:GILD opened at $130.21 on Friday. The business’s 50 day moving average is $129.61 and its 200 day moving average is $135.87. The stock has a market cap of $161.66 billion, a P/E ratio of 17.74 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the company posted $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current year.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Gilead’s Trodelvy with Keytruda for certain patients with advanced triple-negative breast cancer. The potential label expansion could broaden Trodelvy’s commercial opportunity and strengthen Gilead’s oncology pipeline. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: Several analyses remain favorable on GILD. One investment article argues that investors should “buy the distortion” ahead of second-quarter results, while another says the stock still appears inexpensive after delivering roughly 130% total return over five years. Gilead: Buy the Distortion Before Q2 Clears It Up Gilead Stock Stays Cheap on Its Five-Year Run
• Neutral Sentiment: Investor attention is focused on Gilead’s second-quarter 2026 results. Preview articles highlight Wall Street expectations for revenue, earnings and operating metrics, but they do not provide a confirmed earnings surprise. Wall Street Projections for Gilead’s Q2 Metrics
• Positive Sentiment: Analyst coverage remains broadly supportive, with reports noting Gilead’s market outperformance and bullish views on its prospects. However, heightened investor attention alone is not a fundamental catalyst. Do Wall Street Analysts Like Gilead Sciences Stock?
• Negative Sentiment: Erste Group Bank reduced its fiscal 2027 earnings-per-share estimate for Gilead, raising concerns about the company’s future earnings growth. Erste Group Bank Cuts Gilead FY2027 EPS Estimate
• Negative Sentiment: Barclays lowered its Gilead price target to $145. Although the revised target remains above the stock’s referenced trading level, the reduction signals more limited near-term upside and is likely weighing on sentiment. Barclays Lowers Gilead Price Target

Insider Activity

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 67,000 shares of company stock worth $8,687,140. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Royal Bank Of Canada cut their price objective on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Morgan Stanley decreased their target price on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gilead Sciences in a research note on Wednesday. Finally, Citigroup raised their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $157.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.